Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Relapsed/Refractory IIB/IVB Mycosis Fungoides / Sézary Syndrome Patients after Previous Systemic Treatment. EORTC-1652-CLTG “PARCT” | Publicación